Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meds Apotek AB (publ)OSTO:MEDS +3.90%11 Return-on-Tangible-Equity is 18.19% as of Jun. 2026. GuruFocus rates OSTO:MEDS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,062 Retail - Cyclical companies, Meds Apotek AB (publ) ranks worse than 50.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Meds Apotek AB (publ)'s annualized net income for the quarter that ended in Jun. 2026 was kr23 Mil. Meds Apotek AB (publ)'s average shareholder tangible equity for the quarter that ended in Jun. 2026 was kr125 Mil. Therefore, Meds Apotek AB (publ)'s annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 18.19%.
The historical rank and industry rank for Meds Apotek AB (publ)'s Return-on-Tangible-Equity or its related term are showing as below:
OSTO:MEDS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -78.12 Med: -22.03 Max: 9.64
Current: 8.09
During the past 4 years, Meds Apotek AB (publ)'s highest Return-on-Tangible-Equity was 9.64%. The lowest was -78.12%. And the median was -22.03%.
OSTO:MEDS's Return-on-Tangible-Equity is ranked worse than 50.75% of 1062
companies
in the Retail - Cyclical industry
Industry Median: 8.455
vs OSTO:MEDS: 8.09
Meds Apotek AB (publ) (OSTO:MEDS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Meds Apotek AB (publ) Return-on-Tangible-Equity Related Terms
Meds Apotek AB (publ) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Meds Apotek AB (publ)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meds Apotek AB (publ) Return-on-Tangible-Equity Chart
OSTO:MEDS vs AMZN, BABA, PDD: Return-on-Tangible-Equity Comparison
For the Internet Retail subindustry, Meds Apotek AB (publ)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meds Apotek AB (publ) Return-on-Tangible-Equity vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Meds Apotek AB (publ)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Meds Apotek AB (publ)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.19% mean?
Meds Apotek AB (publ) (OSTO:MEDS) has a Return-on-Tangible-Equity of 18.19% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Meds Apotek AB (publ) and its competitors. According to the industry distribution chart, Meds Apotek AB (publ) ranks #539 out of 1062 companies in the Retail - Cyclical industry, placing it in the top 50.8%.
Is Meds Apotek AB (publ)'s Return-on-Tangible-Equity too high?
Meds Apotek AB (publ)'s current Return-on-Tangible-Equity is 18.19%. The Retail - Cyclical industry median Return-on-Tangible-Equity is 8.46. Meds Apotek AB (publ)'s value of 18.19% is 115.1% above this industry median. Based on the distribution chart, Meds Apotek AB (publ) ranks #539 out of 1062 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, Meds Apotek AB (publ) has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Meds Apotek AB (publ)'s Return-on-Tangible-Equity compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Meds Apotek AB (publ) ranks #539 out of 1062 companies for Return-on-Tangible-Equity. This places Meds Apotek AB (publ) in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.46. Meds Apotek AB (publ)'s value of 18.19% is 115.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Retail - Cyclical company?
The median Return-on-Tangible-Equity among Retail - Cyclical companies is 8.46, based on 1,062 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meds Apotek AB (publ)'s current Return-on-Tangible-Equity of 18.19% is 115.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Meds Apotek AB (publ) and its competitors. For the Retail - Cyclical industry, the median Return-on-Tangible-Equity is 8.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meds Apotek AB (publ)'s current Return-on-Tangible-Equity is 18.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meds Apotek AB (publ) stock overvalued right now?
Meds Apotek AB (publ) (OSTO:MEDS) has a current Return-on-Tangible-Equity of 18.19%. The current Return-on-Tangible-Equity is 18.19% and 115.1% above the Retail - Cyclical industry median of 8.46. Meds Apotek AB (publ)'s overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Meds Apotek AB (publ) (OSTO:MEDS), the current Return-on-Tangible-Equity is 18.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Meds Apotek AB (publ) is a full-scale online pharmacy that sells prescription and over-the-counter medicines with permission from the Medical Products Agency, the Swedish Food Agency and the E-Health Agency. The company's pharmacy products include everything in health, well-being, dietary supplements, beauty products, children's products, fitness products, food and drink and home & household products.
11GF Score
Get the complete analysis for OSTO:MEDS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MEDS has been successfully added to your 
